An Observation of Camrelizumab and Anlotinib Third-Line Therapy in Advanced Non-Small Cell Lung Cancer Patients
Objective To discuss the clinical effectiveness of Camrelizumab and Anlotinib third-line therapy in advanced non-small cell lung cancer patients.Methods A retrospective analysis was performed on 82 patients with advanced non-small cell lung cancer who received third-line treatment in Nanyang Central Hospital from February 2021 to February 2023.Among them,41 patients receiving Anrotinib monotherapy were set as the control group,and 41 patients receiving Carrillizumab and Anrotinib therapy were set as the observation group.The therapeutic effect,related clinical indexes,quality of life and adverse drug reactions were compared between the two groups.Results The effective rate of the observation group(43.90%)was higher than that of the control group(21.95%),and the difference was statistically significant(P＜0.05).Before treatment,there were no significant differences in the levels of neuron-specific enolase(NSE),serum carcinoembryonic antigen(CEA)and vascular endothelial growth factor(VEGF)between the two groups(P＞0.05);After treatment,the levels of NSE,CEA and VEGF in both groups were decreased,and the observation group were lower than the control group,the differences were statistically significant(P＜0.05).Before treatment,there was no significant difference in KPS score between the two groups(P＞0.05);After treatment,KPS score in observation group was improved,and observation group was higher than control group,the difference was statistically significant(P＜0.05).The incidence of adverse drug reactions in observation group(36.59%)was lower than that in control group(41.46%),and the difference was not statistically significant(P＞0.05).Conclusion In patients with advanced non-small cell lung cancer,carrellizumab and anlotinib have good clinical efficacy,which can reduce the levels of NSE,CEA and VEGF,improve the quality of life of patients,and do not increase adverse drug reactions,which is worthy of clinical application.
国家科技期刊平台
NSTL
万方数据
维普
